The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial

(2023) The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial. Archives of Medical Science. pp. 1693-1700. ISSN 1734-1922

Full text not available from this repository.

Abstract

Introduction:<bold> </bold>Trehalose is a naturally occurring disaccharide of 2 glucose molecules, which has been suggested as a potential therapeutic agent to reduce blood glucose and ameliorate diabetes-related complications in type 2 diabetes (T2D). This study aimed to determine the efficacy of medium-term trehalose treatment in patients with T2D.<br />Material and methods: A double-blind, randomized, placebo-controlled trial in 40 patients with T2D was undertaken; 20 ingested trehalose 3.3 g/day and 20 placebo (sucrose), for 3 months. Parameters of glycaemic indices, high-sensitivity C-reactive protein (CRP), mood status, and quality of life were measured.<br />Results: CRP was significantly lower with trehalose treatment (-0.62 +/- 0.3 mg/l, p = 0.02); however, no differences in glycaemic indices of fasting blood glucose (FBG) (-7.1 +/- 10.7 mg/dl, p = 0.15), glycated hemoglobin (HbA(1c)) (-0.1 +/- 0.4, p = 0.73), insulin (0.73 +/- 0.8 mu U/ml, p = 0.39), or insulin resistance (HOMA-IR) (0.19 +/- 0.33, p = 0.56) were seen between groups after 12 weeks. Depression and stress scores were lower with trehalose compared to the placebo group (p = 0.02 and p = 0.05, respectively), whilst the quality-of-life score was higher with trehalose compared to placebo (p = 0.03) at the end of study. Between-group differences in these indices did not reach statistical significance (-2.36 +/- 1.20, -2.21 +/- 1.39 and 3.00 +/- 1.76 for depression, stress, and quality-of-life score, respectively) (p > 0.05). The pro-oxidant antioxidant balance (PAB) did not differ between groups (-4.6 +/- 12.8, p = 0.72).<br />Conclusions: 12 weeks of treatment with 3.3 g/day of oral trehalose significantly improves CRP as a marker of inflammation, with potential favourable effects on quality of life, depression, and stress levels, but overall glycaemic control and pro-oxidant-antioxidant balance were unaltered during this time frame.

Item Type: Article
Keywords: trehalose diabetes glycaemic indies quality of life antioxidant randomized controlled trial responses following trehalose ingestion implications oxidative stress risk-factors glucose mellitus model homeostasis autophagy protects General & Internal Medicine
Page Range: pp. 1693-1700
Journal or Publication Title: Archives of Medical Science
Journal Index: ISI
Volume: 19
Number: 6
Identification Number: https://doi.org/10.5114/aoms/159048
ISSN: 1734-1922
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/26423

Actions (login required)

View Item View Item